The microbiome, immunity, and schizophrenia and bipolar disorder

Brain, Behavior, and Immunity

Volumn 62, Issue , 2017, Pages 46-52

  Dickerson, Faith ^a   Severance, Emily ^b   Yolken, Robert ^b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Bipolar disorder; Gastrointestinal; Immunity; Microbiome; Probiotics; Schizophrenia

Indexed keywords

VALPROIC ACID;

ARTICLE; BIPOLAR DISORDER; BRAIN FUNCTION; COGNITION; COMORBIDITY; CORRELATION ANALYSIS; DIGESTIVE SYSTEM INFLAMMATION; DISEASE SEVERITY; GASTROINTESTINAL DISEASE; HUMAN; IMMUNITY; METAGENOMICS; MICROBIOME; MICROFLORA; NONHUMAN; PREVALENCE; SCHIZOPHRENIA; SEQUENCE HOMOLOGY; SPECIES DIVERSITY; TOXOPLASMA GONDII; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY;

BIPOLAR DISORDER; HUMANS; IMMUNITY; MICROBIOTA; SCHIZOPHRENIA;

EID: 85009476052     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.12.010     Document Type: Article

References (61)

1. Anderson, G., Maes, M., Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites. Curr. Psychiatry Rep., 17(2), 2015, 8, 10.1007/s11920-014-0541-1.
2. Bahr, S.M., Tyler, B.C., Wooldridge, N., Butcher, B.D., Burns, T.L., Teesch, L.M., et al. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl. Psychiatry, 5, 2015, e652, 10.1038/tp.2015.135.
3. Bahra, S.M., Weidemann, B.J., Castro, A.N., Walsh, J.W., deLeon, O., Burnett, C.M., et al. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine 2:11 (2015), 1725–1734, 10.1016/j.ebiom.2015.10.018.
4. Bajaj, J.S., Hylemon, P.B., Ridlon, J.M., Heuman, D.M., Daita, K., White, M.B., Monteith, P., Noble, N.A., Sikaroodi, M., Gillevet, P.M., Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 303:6 (2012), G675–G685.
5. Bechter, K., Updating the mild encephalitis hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42 (2013), 71–91, 10.1016/j.pnpbp.2012.06.019.
6. Benros, M.E., Mortensen, P.B., Eaton, W.W., Autoimmune diseases and infections as risk factors for schizophrenia. Ann. NY. Acad. Sci. 1262 (2012), 56–66, 10.1111/j.1749-6632.2012.06638.x.
7. Benros, M.E., Waltoft, B.L., Nordentoft, M., Ostergaard, S.D., Eaton, W.W., Krogh, J., Mortensen, P.B., Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 70:8 (2013), 812–820, 10.1001/jamapsychiatry.2013.1111.
8. Bereswill, S., Munoz, M., Fischer, A., Plickert, R., Haag, L.M., Otto, B., et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One, 5(12), 2010, e15099, 10.1371/journal.pone.0015099.
9. Buscaino, Patologia extraneurale della schizofrenia. Fegato, tubo digerente, sistema reticolo-endoteliale. Acta Neurol. VIII (1953), 1–60.
10. Castro-Nallar, E., Bendall, M.L., Perez-Losada, M., Sabuncyan, S., Severance, E.G., Dickerson, F.B., et al. Composition, taxonomy and functional diversity of the oropharynx microbiome in individuals with schizophrenia and controls. PeerJ, 3, 2015, e1140, 10.7717/peerj.1140.
11. Collado, M.C., Rautava, S., Isolauri, E., Salminen, S., Gut microbiota: a source of novel tools to reduce the risk of human disease?. Pediatr. Res. 77:1–2 (2015), 182–188, 10.1038/pr.2014.173.
12. Dacquino, C., De Rossi, P., Spalletta, G., Schizophrenia and bipolar disorder: the road from similarities and clinical heterogeneity to neurobiological types. Clin. Chim. Acta, 2015, 10.1016/j.cca.2015.02.029.
13. De Angelis, M., Rizzello, C.G., Fasano, A., Clemente, M.G., De Simone, C., Silano, M., et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. Biochim. Biophys. Acta 1762:1 (2006), 80–93, 10.1016/j.bbadis.2005.09.008.
14. de Theije, C.G., Wopereis, H., Ramadan, M., van Eijndthoven, T., Lambert, J., Knol, J., et al. Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav. Immun. 37 (2014), 197–206, 10.1016/j.bbi.2013.12.005.
15. Desbonnet, L., Clarke, G., Traplin, A., O'Sullivan, O., Crispie, F., Moloney, R.D., et al. Gut microbiota depletion from early adolescence in mice: implications for brain and behaviour. Brain Behav. Immun. 48 (2015), 165–173, 10.1016/j.bbi.2015.04.004.
16. Desplat-Jego, S., Johanet, C., Escande, A., Goetz, J., Fabien, N., Olsson, N., et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J. Gastroenterol. 13:16 (2007), 2312–2318.
17. Dickerson, F.B., Stallings, C., Origoni, A., Katsafanas, E., Savage, C.L., Schweinfurth, L.A., et al. Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim Care Companion CNS Disord., 16(1), 2014, 10.4088/PCC.13m01579.
18. Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Katsafanas, E., Khushalani, S., Yolken, R., A combined marker of inflammation in individuals with mania. PLoS One, 8(9), 2013, e73520, 10.1371/journal.pone.0073520.
19. Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Yolken, R., Markers of gluten sensitivity in acute mania: a longitudinal study. Psychiatry Res. 196:1 (2012), 68–71, 10.1016/j.psychres.2011.11.007.
20. Dickerson, F., Stallings, C., Vaughan, C., Origoni, A., Khushalani, S., Yolken, R., Antibodies to the glutamate receptor in mania. Bipolar Disord. 14:5 (2012), 547–553, 10.1111/j.1399-5618.2012.01028.x.
21. Erny, D., de Angelis, A.L., Prinz, M., Communicating systems in the body: how microbiota and microglia cooperate. Immunology, 2016, 10.1111/imm.12645.
22. Fillman, S.G., Sinclair, D., Fung, S.J., Webster, M.J., Shannon Weickert, C., Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl. Psychiatry, 4, 2014, e365, 10.1038/tp.2014.8.
23. Fond, G., Boukouaci, W., Chevalier, G., Regnault, A., Eberl, G., Hamdani, N., et al. The “psychomicrobiotic”: targeting microbiota in major psychiatric disorders: a systematic review. Pathol. Biol. (Paris) 63:1 (2015), 35–42, 10.1016/j.patbio.2014.10.003.
24. Guerra, P.V., Lima, L.N., Souza, T.C., Mazochi, V., Penna, F.J., Silva, A.M., et al. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J. Gastroenterol. 17:34 (2011), 3916–3921, 10.3748/wjg.v17.i34.3916.
25. Gupta, S., Masand, P.S., Kaplan, D., Bhandary, A., Hendricks, S., The relationship between schizophrenia and irritable bowel syndrome (IBS). Schizophr. Res. 23:3 (1997), 265–268.
26. Haddad, P.M., Das, A., Ashfaq, M., Wieck, A., A review of valproate in psychiatric practice. Expert Opin. Drug Metab. Toxicol. 5:5 (2009), 539–551, 10.1517/17425250902911455.
27. Houenou, J., d'Albis, M.A., Daban, C., Hamdani, N., Delavest, M., Lepine, J.P., et al. Cytomegalovirus seropositivity and serointensity are associated with hippocampal volume and verbal memory in schizophrenia and bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 48 (2014), 142–148, 10.1016/j.pnpbp.2013.09.003.
28. Hyland, N.P., Cryan, J.F., Microbe-host interactions: influence of the gut microbiota on the enteric nervous system. Dev. Biol., 2016, 10.1016/j.ydbio.2016.06.027.
29. Jobe, T.H., Harrow, M., Long-term outcome of patients with schizophrenia: a review. Can. J. Psychiatry 50:14 (2005), 892–900.
30. Kohler, O., Benros, M.E., Nordentoft, M., Farkouh, M.E., Iyengar, R.L., Mors, O., Krogh, J., Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71:12 (2014), 1381–1391, 10.1001/jamapsychiatry.2014.1611.
31. Kohler, O., Petersen, L., Mors, O., Mortensen, P.B., Yolken, R., Gasse, C., Benros, M.E., Infections and exposure to anti-infective agents and the risk of severe mental disorders: a nationwide study. Acta Psychiatr. Scand., 2016.
32. Leboyer, M., Berk, M., Yolken, R.H., Tamouza, R., Kupfer, D., Groc, L., Immuno-psychiatry: an agenda for clinical practice and innovative research. BMC Med., 14(1), 2016, 173, 10.1186/s12916-016-0712-5.
33. Lee, Y.T., Hu, L.Y., Shen, C.C., Huang, M.W., Tsai, S.J., Yang, A.C., et al. Risk of psychiatric disorders following irritable bowel syndrome: a nationwide population-based cohort study. PLoS One, 10(7), 2015, e0133283, 10.1371/journal.pone.0133283.
34. Levite, M., Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol. (Oxford) 216:1 (2016), 42–89, 10.1111/apha.12476.
35. Lichtenstein, P., Yip, B.H., Bjork, C., Pawitan, Y., Cannon, T.D., Sullivan, P.F., Hultman, C.M., Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373:9659 (2009), 234–239, 10.1016/s0140-6736(09)60072-6.
36. Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K., Knight, R., Diversity, stability and resilience of the human gut microbiota. Nature 489:7415 (2012), 220–230, 10.1038/nature11550.
37. Lurie, I., Yang, Y.X., Haynes, K., Mamtani, R., Boursi, B., Antibiotic exposure and the risk for depression, anxiety, or psychosis: a nested case-control study. J. Clin. Psychiatry 76:11 (2015), 1522–1528, 10.4088/JCP.15m09961.
38. Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70:7 (2011), 663–671, 10.1016/j.biopsych.2011.04.013.
39. Nielsen, P.R., Benros, M.E., Mortensen, P.B., Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of Danish national registers. Schizophr. Bull., 2013, 10.1093/schbul/sbt200.
40. Rosenblat, J.D., Cha, D.S., Mansur, R.B., McIntyre, R.S., Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 53 (2014), 23–34, 10.1016/j.pnpbp.2014.01.013.
41. Saulnier, D.M., Kolida, S., Gibson, G.R., Microbiology of the human intestinal tract and approaches for its dietary modulation. Curr. Pharm. Des. 15:13 (2009), 1403–1414.
42. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:7510 (2014), 421–427, 10.1038/nature13595.
43. Schoepf, D., Uppal, H., Potluri, R., Heun, R., Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur. Arch. Psychiatry Clin. Neurosci. 264:1 (2014), 3–28, 10.1007/s00406-013-0436-x.
44. Segata, N., Haake, S.K., Mannon, P., Lemon, K.P., Waldron, L., Gevers, D., et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol., 13(6), 2012, R42, 10.1186/gb-2012-13-6-r42.
45. Severance, E.G., Alaedini, A., Yang, S., Halling, M., Gressitt, K.L., Stallings, C.R., et al. Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophr. Res. 138:1 (2012), 48–53, 10.1016/j.schres.2012.02.025.
46. Severance, E.G., Gressit, K.L., Stallings, C., Katsafanas, E., Savage, C., et al. Probioitc normalization of Candida albicans in schizophrenia: a randomized, placebo-controlled, longitudinal pilot study. Brain Behav. Immun., 2016.
47. Severance, E.G., Gressitt, K.L., Stallings, C.R., Katsafanas, E., Schweinfurth, L.A., Savage, C.L., Adamos, M.B., Sweeney, K.M., Origoni, A.E., Khushalani, S., Leweke, F.M., et al. Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder. NPJ Schizophr., 2, 2016, 16018, 10.1038/npjschz.2016.18.
48. Severance, E.G., Gressitt, K.L., Stallings, C.R., Origoni, A.E., Khushalani, S., Leweke, F.M., et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr. Res. 148:1–3 (2013), 130–137, 10.1016/j.schres.2013.05.018.
49. Severance, E.G., Gressitt, K.L., Yang, S., Stallings, C.R., Origoni, A.E., Vaughan, C., et al. Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder. Bipolar Disord. 16:3 (2014), 230–240, 10.1111/bdi.12159.
50. Severance, E.G., Prandovszky, E., Castiglione, J., Yolken, R.H., Gastroenterology issues in schizophrenia: why the gut matters. Curr. Psychiatry Rep., 17(5), 2015, 27, 10.1007/s11920-015-0574-0.
51. Severance, E.G., Yolken, R.H., Eaton, W.W., Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr. Res., 2014, 10.1016/j.schres.2014.06.027.
52. Sherwin, E., Sandhu, K.V., Dinan, T.G., Cryan, J.F., May the force be with you: the light and dark sides of the microbiota-gut-brain axis in neuropsychiatry. CNS Drugs, 2016, 10.1007/s40263-016-0370-3.
53. Tomasik, J., Yolken, R.H., Bahn, S., Dickerson, F.B., Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomized, placebo-controlled trial. Biomark Insights 10 (2015), 47–54, 10.4137/bmi.s22007.
54. Torrey, E.F., Bartko, J.J., Yolken, R.H., Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr. Bull. 38:3 (2012), 642–647, 10.1093/schbul/sbs043.
55. Tseng, P.T., Chen, Y.W., Chung, W., Tu, K.Y., Wang, H.Y., Wu, C.K., Lin, P.Y., Significant effect of valproate augmentation therapy in patients with schizophrenia: a meta-analysis study. Medicine (Baltimore), 95(4), 2016, e2475, 10.1097/md.0000000000002475.
56. Van Snellenberg, J.X., de Candia, T., Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 66:7 (2009), 748–755, 10.1001/archgenpsychiatry.2009.64.
57. Whiteford, H.A., Ferrari, A.J., Degenhardt, L., Feigin, V., Vos, T., The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One, 10(2), 2015, e0116820, 10.1371/journal.pone.0116820.
58. Whitehead, W.E., Palsson, O., Jones, K.R., Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?. Gastroenterology 122:4 (2002), 1140–1156.
59. Xiao, J., Li, Y., Gressitt, K.L., He, H., Kannan, G., Schultz, T.L., et al. Cerebral complement C1q activation in chronic toxoplasma infection. Brain Behav. Immun. 58 (2016), 52–56, 10.1016/j.bbi.2016.04.009.
60. Yolken, R., Adamos, M., Katsafanas, E., Khushalani, S., Origoni, A., Savage, C., et al. Individuals hospitalized with acute mania have increased exposure to antimicrobial medications. Bipolar Disord., 2016, 10.1111/bdi.12416.
61. Yolken, R.H., Severance, E.G., Sabunciyan, S., Gressitt, K.L., Chen, O., Stallings, C., et al. Metagenomic sequencing indicates that the oropharyngeal phageome of individuals with schizophrenia differs from that of controls. Schizophr. Bull. 41:5 (2015), 1153–1161, 10.1093/schbul/sbu197.